SOUTH SAN FRANCISCO, Calif.,
May 26, 2021 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that Raul Rodriguez, the company's
president and chief executive officer, is scheduled to present a
company overview at the Jefferies Virtual Healthcare Conference on
Wednesday, June 2, 2021 at
1:00 p.m. Eastern Time.
To access the live and subsequently archived webcast, go to the
Investor Relations section of the company's website at
www.rigel.com. Please connect to Rigel's website several minutes
prior to the start of the live webcast to ensure adequate time for
any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with hematologic
disorders, cancer and rare immune diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous treatment. The
product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of
chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase
3 clinical trial for the treatment of warm autoimmune
hemolytic anemia (wAIHA)1; a Phase 3 clinical
trial for the treatment of hospitalized patients
with COVID-191; an NIH/NHLBI-sponsored Phase 2
clinical trial for the treatment of hospitalized patients with
COVID-19, in collaboration with Inova Health System; and a Phase
2 clinical trial for the treatment of COVID-19 being
conducted by Imperial College London.
Rigel's other clinical programs include its interleukin
receptor-associated kinase (IRAK) inhibitor program, and a
receptor-interacting serine/threonine-protein kinase (RIP1)
inhibitor program in clinical development with partner Eli Lilly
and Company. In addition, Rigel has product candidates in
development with partners AstraZeneca, BerGenBio ASA, and
Daiichi Sankyo.
Please see www.TAVALISSE.com for full
Prescribing Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Rigel Contact:
Jodi Sievers
Phone: +1 (650)624-1232
Email: ir@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-virtual-healthcare-conference-301299452.html
SOURCE Rigel Pharmaceuticals, Inc.